Curcumin, a potential inhibitor of Up-regulation of TNF-alpha and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway

Biomedical and Environmental Sciences

Volumn 22, Issue 1, 2009, Pages 32-39

  Wang, Shao Ling ^a   Ying, Li ^a   Ying, Wen ^a   Chen, Yan Feng ^a   Na, Li Xin ^a   Li, Song Tao ^a   Sun, Chang Hao ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Adipocyte; Curcumin; Free fatty acids; Inflammation; Insulin resistance

Indexed keywords

CURCUMA LONGA;

EID: 65349126101     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-3988(09)60019-2     Document Type: Article

References (49)

1. Pirro M, Mauriege P, Tchernof A, et al. (2002). Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis 160(2), 377-384.
2. Han P, Zhang Y Y, Lu Y, et al. (2008). Effects of different free fatty acids on insulin resistance in rats. Hepatobiliary Pancreat Dislnt 7(1), 91-96.
3. Goh T T, Mason T M, Gupta N, et al. (2007). Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure. Am J Physiol Endocrinol Metab 292(2), E549-560.
4. Chavez J A, Knotts T A, Wang L P, et al. (2003). A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 278(12), 10297-10303.
5. Hajduch E, Balendran A, Batty I H, et al. (2001). Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 44(2), 173-183.
6. Ragheb R, Medhat A M, Shanab G M, et al. (2008). Links between enhanced fatty acid flux, protein kinase C andv NFkappaB activation, and apoB-lipoprotein production in the fructose-fed hamster model of insulin resistance. Biochem BiophysRes Commun 370(1), 134-139.
7. Anderwald C, Brunmair B, Stadlbauer K, et al. (2007). Effects of free fatty acids on carbohydrate metabolism and insulin signalling in perfused rat liver. Eur J Clin Invest 37(10), 774-782.
8. Yu C, Chen Y, Cline G W, et al. (2002). Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-l)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277(52), 50230-50236.
9. Kershaw E E, Flier J S (2004). Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89(6), 2548-2556.
10. Straub R H, Hense H W, Andus T, et al. (2000). Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 85(3), 1340-1344.
11. Fernandez-Real J M, Vayreda M, Richart C, et al. (2001).Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86(3), 1154-1159.
12. Muller S, Martin S, Koenig W, et al. (2002). Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but notTNF-alpha or its receptors. Diabetologia 45(6), 805-812.
13. Pitsavos C, Tampourloi M, Panaqitakos D B, et al. (2007). Association Between Low-Grade Systemic Inflammation and Type 2 Diabetes Mellitus Among Men and Women from the ATTICA Study. Rev Diabet Stud 4(2), 98-104.
14. Yuan M, Konstantopoulos N, Lee J, et al. (2001). Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293(5535), 1673-1677.
15. Bhatt A B, Dube J J, Dedousis N, et al. (2006). Diet-induced obesity and acute hyperlipidemia reduce IkappaBalpha levels in rat skeletal muscle in a fiber-type dependent manner. Am J Physiol Regul lntegr Comp Physiol 290(1), R233-240.
16. Yu C, Chen Y, Cline G W, et al. (2002). Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1 (-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277(52), 50230-50236.
17. Thompson N M, Norman A M, Donkin S S, et al. (2007). Prenatal and postnatal pathways to obesity: different underlying mechanisms, different metabolic outcomes. Endocrinology 148(5), 2345-2354.
18. Sharma R A. Gescher A J, Steward W P (2005). Curcumin: the story so far. Eur J Cancer 41( 13), 1955-1968.
19. Weber W M, Hunsaker L A, Abcouwer S F, et al. (2005). Anti-oxidant activities of curcumin and related enones. Bioorg Med Chem 13(11), 3811-3820.
20. Moussavi M, Assi K, Gómez-Muñoz A, et al. (2006). Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 27(8), 1636-1644.
21. Shishodia S, Chaturvedi M M, Aggarwal B B (2007). Role of curcumin in cancer therapy. Curr Probl Cancer 31(4), 243-305.
22. Kuroda M, Mimaki Y, Nishiyama T, et al. (2005) Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull 28(5), 937-939.
23. Kumar P A, Suryanarayana P, Reddy P Y, et al. (2005). Modulation of alpha-crystallin chaperone activity in diabetic rat lens by curcumin. Mol Vis 26(11), 561-568.
24. Mahesh T, Balasubashini M S, Menon V P (2005) Effect of photo-irradiated curcumin treatment against oxidative stress in streptozotocin-induced diabetic rats. J Med Food 8(2), 251-255.
25. Patumraj S, Wongeskin N, Sridulyakul P, et al. (2006). Combined effects of curcumin and vitamin C to protect endothelial dysfunction in the iris tissue of STZ-induced diabetic rats. Clin Hemorheol Microcirc 35(4), 481 -489.
26. Pari L, Murugan P (2007). Changes in glycoprotein components in streptozotocin nicotinamide induced type 2 diabetes: influence of tetrahydrocurcumin from Curcuma longa. Plant Foods Hum Nutr 62(1), 25-29.
27. Kunnumakkara A B, Guha S, Krishnan S, et al. (2007). Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factorkappaB-regulated gene products. Cancer Research 67(8), 3853-3861.
28. Shakibaei M, John T, Schulze-Tanzil G, et al. (2007). Lehmann I, Mobasheri A. Suppression of NFkappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase -9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochemical Pharmacology 73(9), 1434-1445.
29. Cheng Y, Ping J, Liu C, Tan Y Z, et al. (2006). Study on effects of extracts from Salvia miltiorrhiza and Curcuma longa in inhibiting phosphorylated extracellular signal regulated kinase expression in rat's hepatic stellate cells. Chin J lntegr Med 12(3), 207-211.
30. Bharti A C, Takada Y, Aggarwal B B (2004). Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 172(10), 5940-5947.
31. Bachmeier B E, Mohrenz I V, Mirisola V, et al. (2008). Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 29(4), 779-789.
32. Kim G Y, Kim K H, Lee S H, et al. (2005). Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 174(12), 8116-8124.
33. Camacho-Barquero L, Villegas I, Sa7acute;nchez-Calvo J M, et al. (2007). Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7(3), 333-342.
34. Xu H, Barnes G T, Yang Q, et al. (2003). Chronic mflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112(12), 1821-1830.
35. Wellen K E, Hotamisigil G S (2005). Inflammation, stress and diabetes. J Clin Invest 115(5), 1111-1119.
36. Bouzakri K, Zierat J R (2007). MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance.J Biol Chem 282(11), 7783-7789.
37. Danesh J, Whincup P, Walker M, et al. (2000). Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321(7255), 199-204.
38. Liang H, Yin B, Zhang B, et al. (2008). Blockade of TNFR1 -mediated TNF-{alpha)signaling protected Wistar rats from diet-induced obesity and insulin resistance. Endocrinology 149(6), 2943-2951.
39. Lin Y, Lee H, Berg AH, et al. (2000). The lipopolysaccharide- activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 275(32), 24255-24263.
40. Fasshauer M, Klein J, Lossner U, et al. (2003). Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes. Horm Metab Res 35(3), 147-152.
41. Ducluzeau P H, Fletcher L M, Vidal H, et al. (2002). Molecular mechanisms of insulin-stimulated glucose uptake in adipocytes. Diabetes Metab 28(2), 85-92.
42. Rotter V, NagaevI, Smith U (2003). Interleukin-6 (IL-6) induce sinsulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278(46), 45777-45784.
43. Juwon K M, Spurlock M E (2005). Palmitate activates the NF-KB transcription factor and induces IL-6 and TNF-a expression in 3T3-L1 adipocytes. J Nutr 135(8), 1841-1846.
44. Nguyen M T, Satoh H, Favelyukis S, et al. (2005). JNK and tumor necrosis factor-a mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 280(42), 35361-35371.
45. Hirosumi J, Tuncman G, Chang L, et al. (2002). A central role for JNK in obesity and insulin resistance. Nature 420(6913), 333-336.
46. Fujishiro M, Gotoh Y, Katagiri H, et al. (2003). Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes. Mol Endocrinol 17(3), 487- 497.
47. Arkan M C, Hevener A L, Greten F R, et al. (2005). IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11(2), 191-198.
48. Cho J W, Lee K S, Kim C W (2007). Curcumin attenuates the expression of IL-lbeta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 19(3), 469-474.
49. Suganami T, Tanimoto-Koyama K, Nishida J, et al. (2007). Role of the Toll-like receptor4/NF14 kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vase Biol 27(1), 84-91